RedHill Biopharma Reports that Opaganib Mechanism Not Impacted by Viral Spike-Protein Mutations, Including Omicron MutationsPRNewsWire • 12/06/21
RedHill Biopharma's Talicia For Bacterial Infections Shows Efficacy Irrespective of Patient BMIBenzinga • 12/02/21
RedHill Biopharma Ltd Announces Talicia: Consistent Efficacy Irrespective of BMIAccesswire • 12/02/21
RedHill Biopharma Data Published in GastroHep Shows Consistent Efficacy of Talicia Irrespective of Patient BMIPRNewsWire • 12/02/21
RedHill Biopharma's Movantik® Added as Preferred and Unrestricted Brand To Major National Medicare Formulary Serving Millions of AmericansPRNewsWire • 12/01/21
RedHill Biopharma's (RDHL) CEO Dror Ben-Asher on Q3 2021 Earnings Call TranscriptSeeking Alpha • 11/30/21
RedHill Biopharma reports increases in net revenues, prescriptions, and gross profit for third quarter of 2021 and accelerates COVID-19 pill programs in light of potential against OmicronProactive Investors • 11/30/21
RedHill Biopharma Reports Operational Highlights and Third Quarter 2021 Financial ResultsPRNewsWire • 11/30/21
RedHill Biopharma to Host Third Quarter 2021 Financial Results and Operational Highlights Webcast on November 30, 2021PRNewsWire • 11/24/21
RedHill Biopharma Announces Closing of $15.5 Million Public Offering of American Depositary SharesPRNewsWire • 11/23/21
RedHill Biopharma Announces Pricing of $15.5 Million Public Offering of American Depositary SharesPRNewsWire • 11/19/21
RedHill Biopharma Announces Underwritten Public Offering of American Depositary SharesPRNewsWire • 11/18/21
RedHill Biopharma says last patient has been enrolled in Part A of the Phase 2/3 study using RHB-107 for non-hospitalized patients with symptomatic coronavirusProactive Investors • 11/15/21
RedHill Biopharma Ltd Announces RedHill: LPI in Part A of RHB-107 P2/3 COVID StudyAccesswire • 11/15/21
RedHill Biopharma Announces Last Patient Randomized in Part A of Ongoing Phase 2/3 COVID-19 Study of Once-Daily Oral RHB-107 in Non-Hospitalized PatientsPRNewsWire • 11/15/21
RedHill Biopharma enters strategic agreement for the sale of its ADS's to South Korea's Kukbo Co via an up to $10 million private placementProactive Investors • 11/09/21
RedHill Biopharma to Present at H.C. Wainwright 7th Annual Israel Conference and German Equity Forum (EKF) 2021PRNewsWire • 11/09/21
RedHill Biopharma and South Korea's Kukbo Co. Announce a Strategic Investment of Up To $10 Million in RedHillAccesswire • 11/08/21
RedHill Biopharma Presents New Talicia(R) and Movantik(R) Data Analyses at ACG 2021Accesswire • 10/25/21
